Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Biogen, Wayfair rise; CrowdStrike, NetApp fall

Por: ABC News Business December 01, 2022

thumbnail

NEW YORK -- Stocks that traded heavily or had substantial price changes Wednesday: Intuit Inc., up $27.88 to $407.59.The maker of TurboTax, QuickBooks and other accounting software beat analysts' fiscal first-quarter revenue and earnings.Biogen Inc., up $13.76 to $305.17.Investors received an encouraging update on a potential Alzheimer's drug being developed by the biopharmaceutical company and partner Eisai.Workday Inc., up $24.60 to... + full article



Similar News

Shares of CrowdStrike fall after 'disappointing' earnings, Morgan Stanley says buy the dip

CNBC USA Tech November 30, 2022

thumbnailGeorge Kurtz, chief executive officer of CrowdStrike Inc., speaks during the Montgomery Summit in Santa Monica, California, U.S., on Wednesday, March 4, 2020. The Montgomery Summit gathers entrepreneurs, investors, and executives to discover the most important innovations in... + más

Another Bad Sign for Tech Stocks—Cloud Spending Is Fading | MarketWatch

CrowdStrike shares tumble on weaker-than-expected growth in new revenue | CNBC


Wayfair added to ‘zombie’ stocks list by equity research firm New Constructs

MarketWatch USA Business November 15, 2022

thumbnail“Companies that inherently struggle to produce real cash flows, like Wayfair, are at risk of their stock price going to $0,” wrote New Constructs CEO David Trainer, in a note. Since New Constructs put Wayfair in its “Danger Zone” in March 2015, the stock has outperformed... + más

A Tesla stock plunge could destroy 'zombie stocks' such as GameStop and Peloton, warns equity research firm New Constructs | MarketWatch

A Tesla stock plunge could destroy 'zombie stocks' such as GameStop and Peloton, warns equity research firm New Constructs | MarketWatch


Biogen tabs veteran pharma leader Viehbacher as next CEO

ABC News USA Health November 11, 2022

thumbnailBiogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm. The company said Thursday that the 62-year-old Viehbacher will become president and CEO... + más

Biogen tabs veteran pharma leader Viehbacher as next CEO | Associated Press

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes


Biogen tabs veteran pharma leader Viehbacher as next CEO

Associated Press USA Health November 11, 2022

thumbnailBiogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the . The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing Michel... + más

Biogen tabs veteran pharma leader Viehbacher as next CEO | ABC News

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes


Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity

Forbes USA Business October 15, 2022

thumbnailGetty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más

Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business

Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC


Biogen to pay $900M to settle allegations of improper physician kickbacks

Fox Business USA Business September 27, 2022

thumbnailAflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs.  The settlement comes after former Biogen... + más

Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC

Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe


Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs

CNBC USA Health September 27, 2022

thumbnailIn this articleA Biogen facility in Cambridge, Massachusetts.Brian Snyder Reuters will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its drugs, the Justice Department announced on Monday.A former Biogen employee... + más

Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business

Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe



About iurex | Privacy Policy | Disclaimer |